225 related articles for article (PubMed ID: 22927810)
1. Allosteric communication across the native and mutated KIT receptor tyrosine kinase.
Laine E; Auclair C; Tchertanov L
PLoS Comput Biol; 2012; 8(8):e1002661. PubMed ID: 22927810
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.
Da Silva Figueiredo Celestino Gomes P; Panel N; Laine E; Pascutti PG; Solary E; Tchertanov L
PLoS One; 2014; 9(5):e97519. PubMed ID: 24828813
[TBL] [Abstract][Full Text] [Related]
3. Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity.
Chauvot de Beauchêne I; Allain A; Panel N; Laine E; Trouvé A; Dubreuil P; Tchertanov L
PLoS Comput Biol; 2014 Jul; 10(7):e1003749. PubMed ID: 25079768
[TBL] [Abstract][Full Text] [Related]
4. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.
Laine E; Chauvot de Beauchêne I; Perahia D; Auclair C; Tchertanov L
PLoS Comput Biol; 2011 Jun; 7(6):e1002068. PubMed ID: 21698178
[TBL] [Abstract][Full Text] [Related]
5. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
6. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.
Chan PM; Ilangumaran S; La Rose J; Chakrabartty A; Rottapel R
Mol Cell Biol; 2003 May; 23(9):3067-78. PubMed ID: 12697809
[TBL] [Abstract][Full Text] [Related]
7. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
[TBL] [Abstract][Full Text] [Related]
8. A change in structural integrity of c-Kit mutant D816V causes constitutive signaling.
Raghav PK; Singh AK; Gangenahalli G
Mutat Res; 2018 Mar; 808():28-38. PubMed ID: 29482074
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
Corbin AS; Demehri S; Griswold IJ; Wang Y; Metcalf CA; Sundaramoorthi R; Shakespeare WC; Snodgrass J; Wardwell S; Dalgarno D; Iuliucci J; Sawyer TK; Heinrich MC; Druker BJ; Deininger MW
Blood; 2005 Jul; 106(1):227-34. PubMed ID: 15746079
[TBL] [Abstract][Full Text] [Related]
10. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
[TBL] [Abstract][Full Text] [Related]
11. Allosteric pathway identification through network analysis: from molecular dynamics simulations to interactive 2D and 3D graphs.
Allain A; Chauvot de Beauchêne I; Langenfeld F; Guarracino Y; Laine E; Tchertanov L
Faraday Discuss; 2014; 169():303-21. PubMed ID: 25340971
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional analysis of KIT gene encoding receptor tyrosine kinase and its interaction with sunitinib and HDAC inhibitors: an in silico approach.
Vanajothi R; Rajamanikandan S; Sudha A; Srinivasan P
Pak J Biol Sci; 2012 Feb; 15(3):121-31. PubMed ID: 22866542
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
[TBL] [Abstract][Full Text] [Related]
14. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2009 Apr; 284(17):11039-47. PubMed ID: 19265199
[TBL] [Abstract][Full Text] [Related]
15. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
16. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
17. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
18. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Vendôme J; Letard S; Martin F; Svinarchuk F; Dubreuil P; Auclair C; Le Bret M
J Med Chem; 2005 Oct; 48(20):6194-201. PubMed ID: 16190746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
